KELOWNA, BRITISH COLUMBIA -- (MARKET WIRE) -- December 19, 2006 -- Sernova Corp. (TSX VENTURE: SVA) today announced it is encouraged by the results of the study conducted with diabetic mice by Toronto researchers, and subsequently reported by several Canadian news outlets. The results appear to support Sernova's approach to treating diabetes in that Sertoli cells secrete, among other things, "substance P", the neuropeptide Toronto researchers injected into diabetic mice to reverse new onset diabetes. Sernova's approach to treating diabetes is to implant beneath the skin of diabetics, a small device containing insulin producing islets to reverse diabetes, and Sertoli cells to naturally protect the islets from the body's immune system.
